Screener
Gyre Therapeutics, Inc. GYRE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| Net (loss) income attributable to common stockholders | $$(2,044)) | $$126) |
| Net (loss) income per share attributable to common stockholders: | ||
| Basic | $$(0.02)) | $$0.00) |
| Diluted | $$(0.03)) | $$(0.03)) |
| Weighted average shares used in calculating net (loss) income per share attributable to common stockholders: | ||
| Basic | 89,119,344 | 87,295,099 |
| Diluted | 89,203,138 | 87,430,167 |
| Other comprehensive (loss) income: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s EPS (diluted)?
- Gyre Therapeutics, Inc. (GYRE) reported EPS (diluted) of -$0.12 in Q2 2026.
- How has Gyre Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Gyre Therapeutics, Inc.'s EPS (diluted) decreased by 300.0% year-over-year, from -$0.03 to -$0.12.
- What is the long-term trend for Gyre Therapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2025), Gyre Therapeutics, Inc.'s EPS (diluted) has grown at a -80.9% compound annual growth rate (CAGR), from -$2.87 to $0.02.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Gyre Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude